ArticleMolecular cancer research : MCR2021
Multiorgan Signaling Mobilizes Tumor-Associated Erythroid Cells Expressing Immune Checkpoint Molecules.
Article in Molecular cancer research : MCR, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 29 citations in OpenAlex.
- Immune-imaging biomarkers: Prognostic value of splenic volume and circulating lymphocytes in upper tract urothelial carcinoma.Oncology letters · 2026Article
- Erythropoietin drug targets and cancer risk: A two-sample Mendelian randomization study.Medicine · 2026Article
- Targeting erythroid progenitor cell metabolism to enhance cancer immunotherapy.NPJ precision oncology · 2026Review
- Hematopoietic Niche Hijacking in Bone Metastases: Roles of Megakaryocytes, Erythroid Lineage Cells, and Perivascular Stromal Subsets.Biomedicines · 2026Review
- Tumor-Induced Rewiring of Splenic Niches: from Immune Organ to Cancer Accomplice.International journal of biological sciences · 2026Review
- Turning cold tumors into hot tumors to ignite immunotherapy.Molecular cancer · 2025Review
- ST2Clinical and translational allergy · 2025Article
- Monocyte-Platelet-Hemoglobin-Hematocrit score and the role of hematological parameters in predicting treatment response to immune checkpoint inhibitors and survival outcomes in non-small cell lung cancer patients-a retrospective study.Translational lung cancer research · 2025Article
- Adaptation of Diqing Tibetan pigs to hypoxic and cold environments through extramedullary hematopoiesis and uncoupled thermogenesis in the liver.BMC biology · 2025Article
- Multifaceted Aspects of Dysfunctional Myelopoiesis in Cancer and Therapeutic Perspectives with Focus on HCC.Biomolecules · 2024Review
- Immunoregulation role of the erythroid cells.Frontiers in immunology · 2024Review
- Targeting the epigenome to reinvigorate T cells for cancer immunotherapy.Military Medical Research · 2023Review
- Erythroid Cells as Full Participants in the Tumor Microenvironment.International journal of molecular sciences · 2023Review
- Cavitation-Mediated Immunomodulation and Its Use with Checkpoint Inhibitors.Pharmaceutics · 2023Review
- Tumor-associated myeloid cells in cancer immunotherapy.Journal of hematology & oncology · 2023Review
- The impact of biological age of red blood cell onFrontiers in physiology · 2023Article
- Extramedullary hematopoiesis contributes to enhanced erythropoiesis during pregnancy via TGF-β signaling.Frontiers in immunology · 2023Article
- The role of erythrocytes and erythroid progenitor cells in tumors.Open life sciences · 2022Review
- Baseline splenic volume as a biomarker for clinical outcome and circulating lymphocyte count in gastric cancer.Frontiers in oncology · 2022Article
- Targeting Stress Erythropoiesis Pathways in Cancer.Frontiers in physiology · 2022Review
Corrections and comments
- Commented on by
Authors and funding
7 authors at 1 institution in 2 countries.
Funding
Abstract
Hematopoietic-derived cells are integral components of the tumor microenvironment and serve as critical mediators of tumor-host interactions. Host cells derived from myeloid and lymphoid lineages perform well-established functions linked to cancer development, progression, and response to therapy. It is unclear whether host erythroid cells also contribute to shaping the path that cancer can take, but emerging evidence points to this possibility. Here, we show that tumor-promoting environmental stress and tumor-induced hemodynamic changes trigger renal erythropoietin production and erythropoietin-dependent expansion of splenic erythroid cell populations in mice. These erythroid cells display molecular features indicative of an immature erythroid phenotype, such as the expression of both CD71 and TER119 and the retention of intact nuclei, and express genes encoding immune checkpoint molecules. Nucleated erythroid cells with similar properties are present in mouse and human tumor tissues. Antibody-mediated erythropoietin blockade reduces tumor-responsive erythroid cell induction and tumor growth. These findings reveal the potential of tumor-induced erythropoietin and erythroid cells as targets for cancer treatment. IMPLICATIONS: : Our study identifies erythropoietin and erythroid cells as novel players in tumor-host interactions and highlights the involvement of multiorgan signaling events in their induction in response to environmental stress and tumor growth.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.